Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
Conditions
Interventions
Elafibranor 80mg
Placebo
Locations
115
United States
The Institute for Liver Health
Chandler, Arizona, United States
Keck Medical Center of USC
Los Angeles, California, United States
Ruane Clinical Research Group Inc.
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of California, Davis Medical Center
Sacramento, California, United States
California Pacific Medical Center - Sutter Pacific Medical Foundation
San Francisco, California, United States
Start Date
September 24, 2020
Primary Completion Date
June 1, 2023
Completion Date
December 1, 2028
Last Updated
April 2, 2026
NCT03301506
NCT03743272
NCT02846896
NCT03112681
NCT02963077
NCT04791527
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions